News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
8,240 Results
Type
Article (1873)
Company Profile (2)
Press Release (6365)
Multimedia
Podcasts (22)
Webinars (1)
Section
Business (2498)
Career Advice (55)
Deals (535)
Drug Delivery (13)
Drug Development (1540)
Employer Resources (15)
FDA (290)
Job Trends (510)
News (4605)
Policy (504)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
Academia (37)
Accelerated approval (2)
Adcomms (1)
Allergies (2)
Alliances (526)
ALS (6)
Alzheimer's disease (47)
Antibody-drug conjugate (ADC) (21)
Approvals (281)
Artificial intelligence (15)
Autoimmune disease (9)
Automation (1)
Bankruptcy (2)
Best Places to Work (406)
BIOSECURE Act (1)
Biosimilars (44)
Biotechnology (1)
Brain cancer (2)
Cancer (146)
Cardiovascular disease (5)
Career advice (44)
Career pathing (1)
CAR-T (8)
CDC (1)
Cell therapy (26)
Clinical research (1307)
Collaboration (48)
Complete response letters (4)
COVID-19 (52)
C-suite (46)
Cystic fibrosis (4)
Data (140)
Denatured (3)
Depression (15)
Dermatology (5)
Diabetes (5)
Diagnostics (39)
Diversity, equity & inclusion (3)
Drug discovery (10)
Drug pricing (29)
Drug shortages (2)
Duchenne muscular dystrophy (4)
Earnings (949)
Editorial (6)
Employer branding (7)
Employer resources (12)
Events (1184)
Executive appointments (28)
FDA (350)
Frontotemporal dementia (1)
Funding (39)
Gene editing (3)
Generative AI (2)
Gene therapy (25)
GLP-1 (50)
Government (145)
Guidances (6)
Healthcare (131)
HIV (1)
Huntington's disease (5)
IgA nephropathy (1)
Immunology and inflammation (43)
Immuno-oncology (2)
Indications (4)
Infectious disease (61)
Inflammatory bowel disease (18)
Inflation Reduction Act (1)
Interviews (6)
IPO (228)
IRA (7)
Job creations (89)
Job search strategy (41)
JPM (11)
Labor market (10)
Layoffs (31)
Leadership (1)
Legal (135)
Longevity (1)
Lung cancer (8)
Lymphoma (52)
Management (2)
Manufacturing (34)
MASH (3)
Medical device (37)
Medtech (38)
Mergers & acquisitions (342)
Metabolic disorders (45)
mRNA (9)
Multiple sclerosis (2)
Neurodegenerative disease (28)
Neuropsychiatric disorders (16)
Neuroscience (126)
NextGen: Class of 2026 (108)
Non-profit (39)
Now hiring (58)
Obesity (35)
Opinion (18)
Ovarian cancer (12)
Pain (6)
Pancreatic cancer (2)
Parkinson's disease (20)
Partnered (1)
Patents (13)
Patient recruitment (4)
People (927)
Pharmaceutical (1)
Pharmacy benefit managers (4)
Phase 1 (386)
Phase 2 (506)
Phase 3 (687)
Pipeline (157)
Policy (22)
Postmarket research (24)
Preclinical (95)
Prostate cancer (3)
Psychedelics (13)
Radiopharmaceuticals (1)
Rare diseases (29)
Real estate (53)
Recruiting (8)
Regulatory (377)
Reports (3)
Research institute (44)
Resumes & cover letters (5)
RNA editing (2)
RSV (6)
Schizophrenia (25)
Series A (12)
Series B (4)
Sickle cell disease (1)
Special edition (5)
Startups (69)
Supply chain (1)
Tariffs (14)
The Weekly (18)
Vaccines (13)
Venture capital (12)
Weight loss (26)
Worklife (1)
Date
Last 7 days (15)
Last 30 days (73)
Last 365 days (579)
2026 (270)
2025 (558)
2024 (708)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)
Location
Africa (25)
Arizona (3)
Asia (430)
Australia (46)
California (262)
Canada (43)
China (14)
Colorado (5)
Connecticut (6)
Delaware (1)
Europe (1309)
Florida (9)
Georgia (6)
Illinois (147)
India (12)
Indiana (13)
Iowa (1)
Japan (11)
Maryland (10)
Massachusetts (159)
Michigan (2)
Minnesota (4)
Missouri (1)
Nebraska (1)
New Hampshire (1)
New Jersey (42)
New York (39)
North Carolina (15)
Northern California (80)
Ohio (5)
Oregon (1)
Pennsylvania (30)
Rhode Island (1)
South America (27)
South Carolina (1)
Southern California (152)
Tennessee (8)
Texas (11)
United States (692)
Utah (3)
Virginia (12)
Washington D.C. (7)
Washington State (5)
Wisconsin (2)
8,240 Results for "abbvie".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.
May 20, 2026
·
2 min read
·
Tristan Manalac
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
March 9, 2026
·
2 min read
·
Heather McKenzie
Pain
AbbVie enters world of pain in up to $715M deal with China’s Haisco
The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx.
April 13, 2026
·
1 min read
·
Annalee Armstrong
Earnings
AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate
Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position of “ample financial capacity.”
April 29, 2026
·
3 min read
·
Gabrielle Masson
Manufacturing
AbbVie commits $1.4B to NC plant in its largest-ever single campus investment
The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.
April 23, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B
AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for the oral pan-KRAS inhibitor KST-6051 in solid tumors.
April 28, 2026
·
1 min read
·
Annalee Armstrong
Drug pricing
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie’s deal with the White House to avoid tariffs. The news comes less than a week after the president announced up to 100% levies on pharma products.
April 7, 2026
·
1 min read
·
Tristan Manalac
Immunology and inflammation
As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
AbbVie’s Skyrizi appears to have stronger efficacy than Johnson & Johnson’s newly approved pill Icotyde, as well as a less frequent dosing schedule that patients could prefer, according to analysts at BMO Capital Markets.
March 30, 2026
·
3 min read
·
Tristan Manalac
Earnings
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
February 4, 2026
·
2 min read
·
Dan Samorodnitsky
Manufacturing
AbbVie Backs Obesity Push With $380M API Production Expansion Project in Illinois
Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they start operations in 2029.
February 24, 2026
·
2 min read
·
Nick Paul Taylor
1 of 824
Next
